Trypsin Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Source, By Application, By End User, By Region & Competition, 2021-2031F

The Global Trypsin Market is projected to expand from USD 99.76 Million in 2025 to USD 140.47 Million by 2031, reflecting a CAGR of 5.87%. As a serine protease primarily extracted from the pancreas of livestock, trypsin functions by breaking down proteins into peptides and amino acids. It acts as a pivotal reagent within the biopharmaceutical sector for cell dissociation, vaccine development, and insulin manufacturing, while also enhancing texture and digestibility in the food industry. The sector's heavy dependence on life sciences fuels this growth; according to the Biotechnology Innovation Organization, revenue for U.S. public bioscience companies increased by 6.8% to $205 billion in 2024, indicating a strong funding landscape that sustains the demand for critical bioprocessing tools like trypsin.

Despite this positive outlook, the market encounters substantial obstacles regarding raw material procurement. The reliance on animal-derived extraction subjects the supply chain to risks involving livestock diseases and viral contamination, necessitating strict regulatory oversight. These safety issues require rigorous, expensive purification procedures to satisfy pharmaceutical standards. Consequently, the instability of animal sourcing and the difficulty of guaranteeing pathogen-free products generate significant bottlenecks that hinder the global scalability and commercial reach of trypsin products.

Market Driver

The expansion of the biopharmaceutical sector and vaccine production serves as a major catalyst for the Global Trypsin Market, fueled by the enzyme's essential role in cell culture protocols. Trypsin remains the standard proteolytic agent for harvesting adherent cells and tissue dissociation, a critical step in manufacturing viral vectors and vaccines. As pharmaceutical leaders ramp up production to address infectious diseases, the demand for high-grade trypsin for upstream bioprocessing has escalated. This momentum is highlighted by significant infrastructure investments, such as Sanofi's May 2024 announcement of a $586 million investment to open an advanced vaccine manufacturing facility in Toronto, which directly drives operational demand for key reagents.

Furthermore, the market is driven by the enzyme's critical role in commercial insulin manufacturing, where it is used to enzymatically cleave proinsulin into active insulin. This function is essential for addressing the growing global need for diabetes treatments. According to the World Health Organization, the number of adults with diabetes worldwide exceeded 800 million in 2024, placing immense pressure on supply chains to boost therapeutic production. Major manufacturers are responding with rapid infrastructure expansion; for example, Novo Nordisk announced a $4.1 billion investment in June 2024 to construct a second fill and finishing facility in the US, underscoring the aggressive scaling of insulin operations dependent on trypsin.

Market Challenge

The dependence on animal-derived extraction poses a significant barrier to the scalability of the Global Trypsin Market. Because trypsin is primarily sourced from the pancreas of livestock, such as pigs and cattle, the supply chain is intrinsically susceptible to biological risks and agricultural volatility. This reliance exposes manufacturers to abrupt disruptions from epizootic outbreaks, which limit raw material volumes and trigger strict regulatory embargoes on animal by-products from impacted areas.

These biological threats result in market instability. According to the World Organisation for Animal Health, the continued spread of African Swine Fever in 2024 impacted domestic swine populations in more than 60 countries, severely limiting the trade and availability of porcine materials needed for trypsin extraction. Such widespread disease prevalence compels manufacturers to implement complex safety measures to ensure pathogen-free ingredients. The consequent need for rigorous viral inactivation and purification increases production costs and lead times, creating a major bottleneck that hampers the industry's capacity to efficiently satisfy the biopharmaceutical sector's growing demand.

Market Trends

The integration of trypsin into automated high-throughput proteomics workflows is fundamentally altering the market, as research institutions require enzyme solutions capable of delivering exceptional consistency for large-scale sample preparation. Modern analytical platforms demand highly active and stable trypsin to ensure reproducible and complete protein digestion within shorter timeframes, a necessity for population-scale health research. This shift toward massive, streamlined processing drives the uptake of specialized reagent grades that support continuous operation. As noted in a January 2025 press release from Thermo Fisher Scientific, the UK Biobank Pharma Proteomics Project selected the company's platform to analyze over 5,400 proteins across roughly 600,000 samples, a scale that highlights the rising volume of enzymatic reagents required for high-throughput biological studies.

Additionally, the rising application of trypsin in cultivated meat and cellular agriculture marks a growing frontier for consumption, where the enzyme is essential for harvesting biomass and maintaining cell viability during expansion. As this emerging sector moves from pilot research to commercial manufacturing, significant investment is being focused on optimizing bioprocesses and securing supply chains for key inputs. This emphasis on scaling is crucial for making cell-based protein products commercially accessible. According to The Good Food Institute's March 2025 report, the sector showed resilience with Prolific Machines securing a $54.6 million Series B funding round, an investment dedicated to advancing biomanufacturing technologies that depend on these critical cell culture components.

Key Market Players

• Merck KGaA
• Novozymes A/S, part of Novonesis Group
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc
• Sartorius AG
• Bioseutica BV
• Biozym Scientific GmbH
• PromoCell GmbH
• Promega Corporation
• Bovogen Biologicals Pty Ltd

Report Scope

In this report, the Global Trypsin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Trypsin Market, By Source

• Porcine
• Bovine
• Others

Trypsin Market, By Application

• Biotechnology and Pharmaceutical Industry
• Food Industry
• Cosmetics and Personal Care
• Waste Treatment
• Others

Trypsin Market, By End User

• Research
• Diagnostics
• Industrial use

Trypsin Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Trypsin Market.

Available Customizations:

Global Trypsin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).